AMENDMENTS TO THE CLAIMS

1. (Original) A carrier with a non-cationic surface, which can accumulate on a damaged site of a tissue.

2. (Original) A carrier according to claim 1, wherein the surface is a membrane.

3. (Original) A carrier according to either one of claims 1 and 2, wherein the tissue is a vessel.

4. (Original) A carrier according to claim 3, which can diffuse outside the vessel.

5. (Currently amended) A carrier according to ~~either one of claims 3 and 4~~ claim 3, wherein the vessel is a blood vessel.

6. (Original) A carrier according to claim 1, wherein the damage reaches an endothelial cell.

7. (Original) A carrier according to claim 1, wherein the damage comprises those that result from laser, inflammation, ischemic disorder, ischemia-reperfusion damage, bacterial toxin, oxidative stress, tumor or thrombus formation, or bleeding.

8. (Original) A carrier according to claim 7, wherein the inflammation is brain edema.

9. (Original) A carrier according to claim 7, wherein the ischemic disorder is cerebral ischemic disorder.

10. (Original) A carrier according to claim 7, wherein the ischemia-reperfusion damage is ischemia-reperfusion-induced organ damage.

11. (Currently amended) A drug transporter comprising the carrier of ~~any one of claims 1 to 10~~ claim 1.

12. (Original) A pharmaceutical composition comprising the drug transporter of claim 11 incorporating or carrying a drug.

13. (Original) A pharmaceutical composition according to claim 12, which functions as a drug for controlling a platelet function.

14. (Original) A pharmaceutical composition according to claim 13, wherein the platelet function to be controlled comprises hemostasis, antithrombotic formation, thrombolysis or antiatherogenic action.

15. (Original) A pharmaceutical composition according to claim 12, wherein the drug is at least one selected from a group consisting of substances that are activated by light, change in temperature, change in pH, ultrasound, uptake of an inflammation-mediating cell or enzyme degradation; hemostatic agents; antithrombotic agents; thrombolytic agents; antitumor agents; and antiatherogenic agents.

16. (Original) A pharmaceutical composition according to claim 15, wherein the inflammation-mediating cell is a lymphocyte, a leukocyte, a macrophage or a platelet.

17. (Currently amended) A drug delivery method comprising allowing the pharmaceutical composition according to ~~any one of claims 12 to 16~~ claim 12 to accumulate on a damaged site of a tissue.

18. (Currently amended) A drug control method comprising allowing the pharmaceutical composition according to ~~any one of claims 12 to 16~~ claim 12 to accumulate on a damaged site of a tissue and allowing the drug to act on the damaged site.

19. (Original) A method according to claim 18, wherein the action of the drug is controlled by accumulation of the carrier, diffusion of the carrier or activation of the carrier.

20. (Original) A method according to any one of claims 17 to 19, wherein the tissue is a vessel.

21. (Original) A method according to claim 20, wherein the vessel is a blood vessel.

22. (Original) A method for assessing a function of a carrier comprising observing the behavior of the carrier within a tissue under a high-speed confocal widefield microscope.

23. (Original) A method according to claim 22, wherein the observation of the carrier behavior within a tissue is performed in multi-color and in real time.

24. (Original) A method according to claim 22, wherein the carrier has a non-cationic surface.

25. (Original) A method according to claim 24, wherein the surface is a membrane.

26. (Original) A method according to claim 22, wherein the tissue is a vessel.

27. (Original) A method according to claim 26, wherein the vessel is a blood vessel.